Top Markets
#1 Doge Strategy Doge Strategy +1,105,414.43%
#2 Noon Noon +10,549.79%
#3 Siren Siren +110.82%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +43.50%
#6 Gigachad Gigachad +25.48%
#7 Ontology Ontology +20.07%
#8 TRIA TRIA +18.98%
#9 Echelon Prime Echelon Prime +18.98%
#10 Win Win +17.98%
Coin of the day
Doge Strategy Doge Strategy
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Classement en actions #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Prix de l'action
$0.0416118
Capitalisation boursière
$12.78M
Changement (1 jour)
1.72%
Changement (1 an)
-22.01%
Pays
AU
Échange Noxopharm Limited (NOX)

Catégorie

Healthcare
Bénéfices pour Noxopharm Limited (NOX)
Bénéfices en Dec 2025 TTM : $-4.82M
Selon les derniers rapports financiers de Noxopharm Limited, les bénéfices actuels de l'entreprise sont de $-4.82M. En 2024, l'entreprise a réalisé un bénéfice de $-3.99M, une augmentation par rapport à celui de 2023 qui était de $-14.02M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Noxopharm Limited de 2016 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-4.82M 49.79%
2025 $-3.22M -19.45%
2024 $-3.99M -71.53%
2023 $-14.02M -15.43%
2022 $-16.58M 136.55%
2021 $-7.01M 23.32%
2020 $-5.68M -50.43%
2019 $-11.46M -19.51%
2018 $-14.24M 507.24%
2017 $-2.35M 334.19%
2016 $-540.21K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -424,852.71%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -96,506.98%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -108,705.27%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -44,485.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -33,617.45%
AU